Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 29, 2008

 

 

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33185   33-0927979

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

4350 La Jolla Village Drive, Suite 950

San Diego, CA 92122

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (858) 373-1500

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item  7.01 Regulation FD Disclosure.

Representatives of MediciNova, Inc. (the “Registrant”) will be making a corporate presentation at various investor meetings commencing April 29, 2008. A copy of the slide presentation to be used by the Registrant at these meetings is attached hereto as Exhibit 99.1.

The information in this Current Report, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for any purpose, including for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item  9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

  

Description

99.1    Slide presentation of the Registrant


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MEDICINOVA, INC.

Dated: April 29, 2008

  By:  

/s/ Shintaro Asako

   

Shintaro Asako

Vice President and Chief Financial Officer


EXHIBIT INDEX

 

Exhibit

  

Description

99.1    Slide presentation of the Registrant
Slide presentation of the Registrant
Accelerating
the global development
and commercialization of
innovative pharmaceuticals
April 2008
Exhibit 99.1


©
MediciNova, Inc. 2008
2
Statements in this presentation that are not historical in nature constitute forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-
looking statements include, without limitation, statements regarding our clinical trials supporting safety and efficacy
of product candidates and the potential novelty of such product candidates as treatments for disease, plans and
objectives for clinical trials and product development, strategies, future performance, financial condition, liquidity
and capital resources. These forward-looking statements may be preceded by, followed by or otherwise include
the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "would," or
similar expressions. Actual results or events may differ materially from those expressed or implied in any forward-
looking statements due to various factors, including, without limitation, the risks and uncertainties inherent in
clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for
product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages
of product development, the risk of delays or failure to obtain or maintain regulatory approval, the risk of failure of
the third parties upon whom we rely to conduct our clinical trials and manufacture our product candidates to
perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment,
completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the
execution of clinical trials and the timing, cost and design of future clinical trials and research activities; the timing
of expected filings with the FDA; our failure to execute strategic plans or strategies successfully; our collaborations
with third parties; the availability of funds to complete product development plans and our ability to raise sufficient
capital when needed; intellectual property or contract rights; and the other risks and uncertainties described in our
filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended
December 31, 2007. Undue reliance should not be placed on these forward-looking statements, which speak only
as of the date hereof. We disclaim any intent or obligation to revise or update these forward-looking statements.
Forward-Looking Statements
Forward-Looking Statements


©
MediciNova, Inc. 2008
3
Development Company Focused on Differentiated Product Candidates
Unique access to differentiated, potentially high-value assets primarily from Japanese
alliances
New Approaches to Treat Serious Medical Conditions:
MN-221: IV Status Asthmaticus candidate
Potential $500 M US opportunity for MediciNova
MN-166: Oral Multiple Sclerosis candidate
In 2006, approximately $7.2 B in worldwide MS therapeutic sales*
Diverse Pipeline:
Six compounds with applications in multiple disease areas
Corporate Overview:
Corporate Overview:
MediciNova, Inc.
MediciNova, Inc.
*Source: MedAdNews, June 2007


©
MediciNova, Inc. 2008
4
In-License:
Product candidates with significant clinical or preclinical
data
Conduct Proof-of-Concept Clinical Trials:
Conduct Phase I and Phase II clinical trials to
demonstrate efficacy of compound
Two Pathways Towards ROI After Phase II:
Continue internal development of compound towards
commercialization
Seek partnership for further development of compound
Business Model:              
Business Model:              
Return On Investment
Return On Investment


©
MediciNova, Inc. 2008
5
NDA
MN-221 Development Plan
MN-221 Development Plan
Note: Development plans / timelines for MN-221 are subject to change
*Anticipated commencement and completion dates based on current projections
**We also plan to conduct an advanced clinical trial of MN-221 in pediatric patients with status asthmaticus;
however, we have not yet determined whether this clinical trial will be initiated in conjunction with the other
planned Phase III clinical trials or after NDA submission
Filing as early as 2H’10


©
MediciNova, Inc. 2008
6
Definition:
Long-lasting and severe asthma episode that is not responsive to
initial bronchodilator or corticosteroid therapy
MN-221:
Novel, highly selective
2-adrenergic receptor agonist
Greater selectivity
Partial agonist for
1 receptor in the heart
Full agonist for
2 receptor in the lungs
Improved safety (fewer cardiovascular side effects) compared to
older
-agonists
IV formulation for acute hospital use
Reliable and rapid delivery
Positive Phase IIa
results reported in October 2007
MN-221: A New Approach to
MN-221: A New Approach to
Treating Status Asthmaticus
Treating Status Asthmaticus


©
MediciNova, Inc. 2008
7
Market Opportunity:
Approximately 1.9 million emergency room visits in the US each year*
500,000 hospitalizations
Approximately 4,000 deaths annually in the US*
Potential $500 M market opportunity for MediciNova
Current Standard of Care*:
Beta agonists (all patients)
Inhaled or nebulized
Corticosteroids (66-77% of patients)
IV or oral
*Source: National Center for Health Statistics / CDC
MN-221: Market Opportunity
MN-221: Market Opportunity


©
MediciNova, Inc. 2008
1.
Proven mechanism of action (
2
-adrenergic
agonist)
2.
Rapid, reliable IV delivery (vs. inhaled / nebulized)
3.
Safer (greater selectivity = fewer cardiovascular SE)
8
Competitive Advantages of
Competitive Advantages of
MN-221
MN-221


©
MediciNova, Inc. 2008
9
Phase IIa study design
Randomized, placebo-controlled, double-blind, sequential dose escalation
23 subjects with mild-to-moderate asthma
Primary objective
To determine the efficacy of a single 15-minute treatment with intravenous MN-221
Secondary objective
To determine the MTD (Maximum Tolerated Dose) 
Primary endpoint met in Phase IIa study completed October 2007
Achieved statistical significance in its primary endpoint of mean change in FEV1 from baseline
at 15 minutes at doses of 3.5, 10, 16, and 30 micrograms/min of MN-221 compared to placebo
No clinically significant cardiovascular, ECG or vital sign changes, or any other safety concerns
observed at any dose tested
60 micrograms/min x 15 min (900 mcg) dose a possible MTD of MN-221
MN-221: Positive Phase IIa data
MN-221: Positive Phase IIa data


©
MediciNova, Inc. 2008
Change from Pre-Infusion FEV1 at 15 min (ITT)
Placebo
.35
ug/min
1.0
ug/min
3.5
ug/min
10 
ug/min
16 
ug/min
30 
ug/min
MN-221-CL-002: Primary
MN-221-CL-002: Primary
Efficacy Variable
Efficacy Variable
10


©
MediciNova, Inc. 2008
MN-221: Safety
MN-221: Safety
Phase IIa
Safety Findings:
No clinically significant cardiovascular, ECG or vital sign changes, or any other safety
concerns observed at doses up to 30 micrograms/minute for 15 minutes or any time
point thereafter
60 micrograms/minute infusion improved FEV1 significantly (p< 0.0001) without clinically
significant cardiovascular, ECG or vital sign changes; however, the safety trend led us to
believe that this is a possible MTD and higher doses should not be tested
Safety Database:
MN-221
has
been
tested
in
over
300
subjects
in
the
US
and
Europe
to
date
Subjects have had infusions with no clinically significant adverse events at:
16 micrograms/minute for up to 4 hours and at lower doses for up
to 24 hours
11


©
MediciNova, Inc. 2008
Commence two Phase IIb studies to test efficacy of MN-221 in status asthmaticus
patients in the emergency room
Single Blind (~32 patients)
Anticipated commencement date: 1H’08
Results expected as early as 2H’08
Double Blind (~200 patients)
Anticipated commencement date: 2H’08
Results expected as early as 2H’09
Commence second Phase IIa study in stable asthmatic patients (~20 patients) for
extended dosing (4 hour infusion) 
Anticipated commencement date: 1H’08
Results expected as early as 2H’08
MN-221: Next Steps
MN-221: Next Steps
12


©
MediciNova, Inc. 2008
13
MN-166 Overview
MN-166 Overview
Multiple Sclerosis
Autoimmune disease
Progressive loss of
neuromuscular function
Relapsing forms
Progressive forms
Damage to myelin sheath
Damage to neuronal axon


©
MediciNova, Inc. 2008
14
Multiple Sclerosis Market:
Approximately $7.2 B worldwide sales in 2006*
Current Standard of Care:
Beta interferons, Copaxone
®
, Tysabri
®
Administered either by intramuscular or subcutaneous injection or infusion
MN-166:
Anti-inflammatory
and
neuroprotective
properties
in
vitro
and
in
vivo
Stimulates Th2 cytokine production and neurotrophic
factor release
Cerebrovasodilator
Inhibits leukotrienes, phosphodiesterases, Th1 cytokine production, nitric oxide
and reactive oxygen species production
Demonstrated effects on brain volume
Targets both primarily chronic aspects of multiple sclerosis
Oral administration
MN-166 Overview
MN-166 Overview
*Source: MedAdNews, June 2007


©
MediciNova, Inc. 2008
15
Description
Efficacy
(relapse rate)
Current agents offer only 30-50% relapse reduction
Neutralizing antibodies can diminish efficacy over time
Most
patients
ultimately
progress;
neurodegeneration
leads
to functional disability
AEs
including flu-like symptoms
SAEs
Rare
but
fatal
PML
with
Tysabri
®
Safety issues with pipeline drugs
Safety/
tolerability
Injections –
daily or weekly
Infusions –
monthly
Administration
Increasing interest in combination therapies given
sub-optimal
efficacy
with
current
“core”
agents
Black box on combination with Tysabri, REMS program
Combination
Demonstrated neuroprotection, that is, reduction in disease
progression,  would be groundbreaking
Historically, anti-inflammatory agents have shown little
impact on disease progression
Axonal
Protection
There Are Substantial         
There Are Substantial         
Unmet Needs in MS
Unmet Needs in MS


©
MediciNova, Inc. 2008
Placebo-controlled, randomized, double-blind Phase II study:
Year 1 -
0, 10 mg tid, 20 mg tid
Year 2 -
10 mg tid, 20 mg tid
n ~ 100 MS patients/group @ 25 sites in Serbia, Ukraine, Belarus, Bulgaria and
Romania
Key inclusion criteria:
Males or females aged 18 to 55 years, with relapsing remitting (RR) and/or
secondary progressive (SP) Multiple Sclerosis with continued relapses;
A
definite
diagnosis
of
relapsing
MS
using
the
new
International
Committee
recommendations (MacDonald Criteria);
One MRI scan taken two weeks prior to treatment start using a standardized MRI
protocol with at least one Gd-enhancing lesion;
An EDSS score of 5.5 or less at the screening and baseline visits.
Current Clinical Studies: MN-
Current Clinical Studies: MN-
166-CL-001
166-CL-001
16


©
MediciNova, Inc. 2008
MN-166 Effects Outcomes Related to Disease Progression in RRMS Patients
Clinical and MRI Outcomes:
Prolong time to relapse (by 127 days.)
Sustained disability progression was significantly less likely (~50%)
Reduced Brain Volume Loss
Reduced Conversation of Acute Lesions to Persistent Black Holes
Mechanisms of Action
Stimulates Neurotrophic
Growth Factor Release
Inhibits nitric oxide and reactive oxygen species production
Inhibits
Th1
cytokine
production
(IFN-
,
TNF-
,
IL-1
,
IL-6)
Pilot studies found reduced relapse rate and Th1
Th2 cytokine shift
Phosphodiesterase
IV and Leukotriene
inhibitor
17
P-Value:
0.044
P-Value:
0.030
MN-166
MN-166
Targets
Targets
Primarily
Primarily
Chronic
Chronic
Aspects
Aspects
of
of
MS
MS
P-Value:
0.026
P-Value:
0.011


©
MediciNova, Inc. 2008
18
Acute Efficacy Demonstrated:
Acute Efficacy Demonstrated:
Time to First Relapse
Time to First Relapse


©
MediciNova, Inc. 2008
TREATMENT
Time Period
Placebo to Active
(N=100)
30 mg
(N=94)
60 mg
(N=98)
1 Year
8 (8.0%)
5 (5.3%)
4 (4.1%)
2 Years
8/51 (15.7%)
13/49 (26.5%)
10 (10.6%)
10 (10.2%)
21/100 (21%)
20/194 (10.4%)
p=0.0264
19
Disability Progression is defined as a sustained increase in EDSS
(increase in EDSS
1 maintained for four consecutive months)
Sustained Disability Progression
Sustained Disability Progression


©
MediciNova, Inc. 2008
20
N=71                             1.59
Chronic Efficacy Demonstrated:  
Chronic Efficacy Demonstrated:  
Effects on Brain Volume
Effects on Brain Volume
N=70                                             1.79
N=34                                                             
2.08
N=45                                                             
2.12
Percent Brain Volume Reduction
Percent Brain Volume Reduction (0 -
24 months)
Brain volume loss was significantly less (p=0.030) in patients receiving 60 mg
per day of MN-166 for 24 months compared to the other treatment groups


©
MediciNova, Inc. 2008
21
Reduction of
Persistent Blackion
Parameter
Treatment Groups
Placebo
30 mg/day
60 mg/day
# Patients w. New Lesions at Month 2
72
64
56
Mean Proportion of Lesions Evolving to PBH
0.24
0.20
0.16
Relative Risk (for Evolution to PBH) vs. placebo
-
0.74
0.63
p Value
-
0.074
0.011
MN-166 treatment at 60 mg per day significantly reduced the relative risk for conversion of new
inflammatory
lesions
identified
at
month
two
to
Persistent
Black
Holes
(PBH),
an
MRI
indicator
of
neuronal loss, eight months later at month ten by 37 percent (p=0.011); such lesions that remain
unchanged for eight months are considered PBHs
as compared to transient inflammatory lesions
that are more closely associated with relapses.
MN-166 treatment at 30 mg per day resulted in a trend toward reducing evolution to PBH
(p=0.074).
Loss of brain volume and development of PBHs
on MRI have been shown to correlate               
with clinical progression and disability in MS patients.
Reduction of Persistent Black Hole (PBH)
Reduction of Persistent Black Hole (PBH)
Formation, a Sign of Axonal Loss
Formation, a Sign of Axonal Loss


©
MediciNova, Inc. 2008
22
MN-166 was very well tolerated in Phase II study:
89%
(264 of 297) of subjects completed the first 12 months of the study
82.5% (245 of 297) of subjects completed the full 24 months of the study
Discontinuation
due
to
adverse
effects
was
infrequent
(5.1%
in
60
mg/day
for
24
months,
2.1%
in 30 mg/day for 24 months, 2.0% in placebo to 60 mg/day, 1.9% in placebo to 30 mg/day)
Adverse effects were generally mild and self-limiting
GI adverse effects as a group and depression were the only adverse events to occur more
frequently in MN-166-treated than in placebo-treated subjects
Tolerance to the GI side effects occurred rapidly (2-4 days) and tended to occur early in
treatment whether MN-166 treatment was initiated in Year 1 or Year 2
Mild-to-moderate depression was reported in 8 subjects; depression is common in MS
patients and was reported only towards the end of the study
No significant increase in adverse laboratory or ECG findings was observed
20 serious adverse events were reported; all were not
or unlikely
to be attributable to
treatment
No deaths occurred in the study
MN-166 Overview-Safety
MN-166 Overview-Safety


©
MediciNova, Inc. 2008
Compound
Sponsor
Current
Phase
Safety Profile
from Phase II trials
MN-166
MediciNova
Phase II
Mild, transient GI upset
FTY 720
Novartis
Phase III
Blood pressure
Heart rate
Dyspnea
Liver
enzymes
Lymphopenia
Cladribine
Merck
Serono
Phase III
Fever
Nausea,
Vomiting
Leucopenia
BG-12
Biogen-Idec
Phase III
H/A,
Nasopharyngitis
GI
disorders
Liver
enzymes
Laquinimod
Teva
Phase III
Liver enzymes
Arthralgia
Fibrinogen
Hemoglobin
Safety Comparison with Other
Safety Comparison with Other
Oral Agents
Oral Agents
23


©
MediciNova, Inc. 2008
24
Commercially-Attractive
Commercially-Attractive
Diversified Portfolio
Diversified Portfolio


©
MediciNova, Inc. 2008
25
MN-221 for Status Asthmaticus
Single-blind
Phase
IIb
study
to
test
efficacy
-
commencement
date:
1H’08
Results as early as 2H’08
Double-blind
Phase
IIb
study
to
test
efficacy
-
commencement
date:
2H’08
Results as early as 2H’09
Second
Phase
IIa
study
for
extended
dosing
-
commencement
date:
1H’08
Results as early as 2H’08
MN-166 for Multiple Sclerosis
Announced Two-Year Phase II results –
April 7, 2008
Pursue corporate partnership to further development
Medicinova
is constantly evaluating opportunities to partner MN-166
and other product candidates
Near-Term Clinical
Near-Term Clinical
Milestones
Milestones


©
MediciNova, Inc. 2008
26
Dual Listing:
MNOV (NasdaqGM), December 2006
4875 (Osaka –
Hercules), February 2005
Limited liquidity due to low float
Cash: $70.6 M as of 12/31/07
Market cap as of 4/15/08: ~$49.6 M
Shares outstanding: 11.9 M
Key Financials
Key Financials


©
MediciNova, Inc. 2008
27
Leadership
Years
Experience
Background
Yuichi Iwaki, MD, PhD
Yuichi Iwaki, MD, PhD
CEO & President
32
Prof. USC, Formerly Prof. Pitt;
Advisor to JAFCO, Tanabe
Director, Avigen, Inc.
Richard Gammans, PhD, MBA
Richard Gammans, PhD, MBA
Gammans, PhD, MBA
, PhD, MBA
Chief Development Officer
30
Incara, Indevus, BMS
Kenneth W. Locke, PhD
Kenneth W. Locke, PhD
Chief Scientific Officer
23
Tanabe Research Laboratories USA,
Indevus, Hoechst
Shintaro
Shintaro
Asako, CPA
Asako, CPA
, CPA
Chief Financial Officer
9
KPMG USA (Audit), Arthur Andersen USA
Masatsune
Masatsune
Okajima, CMA
Okajima, CMA
, CMA
VP, Head of Japanese Office
16
Daiwa Securities SMBC,
Sumitomo Capital Securities, Sumitomo Bank
Management Team with Global
Management Team with Global
Experience
Experience


©
MediciNova, Inc. 2008
28
MN-221 (Status Asthmaticus):
Proven mechanism of action
Highly selective with improved safety profile vs. standard of care
Low risk / high reward proposition
Positive efficacy data
Low development costs to market
MN-166 (Multiple Sclerosis):
Current treatment of MS represents significant unmet medical need
Multi-billion dollar market opportunity
Both chronic and acute efficacy have been demonstrated in clinical studies
Robust pipeline
Six compounds with applications in multiple disease areas
Investment Highlights
Investment Highlights